Rentschler expands development and production capacities
German biopharmaceutical contract manufacturing organisation Rentschler Biotechnologie is expanding its facilities, buildings and laboratory units at the company's site in Laupheim, Germany. This will increase production capacities for antibodies and mammalian cell culture-derived proteins and will create more than 100 jobs.
German biopharmaceutical contract manufacturing organisation Rentschler Biotechnologie is expanding its facilities, buildings and laboratory units at the company's site in Laupheim, Germany. This will increase production capacities for antibodies and mammalian cell culture-derived proteins and will create more than 100 jobs.
The Rentschler Group of companies, which recently sold its otc business, will invest e50m in its biotechnology segment to build two 2,500-litre fermentation suites for market production and several smaller suites ranging from 250 to 500 litres for clinical supplies.
The first new production line is planned to go into operation early in 2008. In the future, 10 independent GMP facilities will be available for the production of biopharmaceuticals.
At its 3,500m2 state-of-the-art facilities in Laupheim, Rentschler Biotechnologie presently has the capacity for manufacturing clinical supplies as well as market supply of low-dosed drugs such as cytokines. By setting up additional fermenter suites, the Rentschler Group will strengthen its biotechnology business of custom manufacturing services from cell line development to large-scale cGMP production, registration of drugs and fill and finish.
"By expanding our production capacity we will establish Rentschler Biotechnologie as a market supplier of antibodies," said ceo Dr Nikolaus F. Rentschler.